Discussion—The Usefulness of Biotechnology Firms' Drug Development Status in the Evaluation of Research and Development Costs

Aboody D. Lev B. . 1998. “The Value Relevance of Intangibles: The Case of Software Capitalization.” Journal of Accounting Research 36 (Supplement): 161–191.

Arnst C. 2002. “How Drug News Leaks to Investors.” Business Week (May 6): 32–33.

Copeland T. E. Antikarov V. . 2001. Real Options: A Practitioner's Guide. New York: Texere Inc.

Darby M. R. Liu Q. Zucker L. G. . 1999. “Stakes and Stars: The Effect of Intellectual Human Capital on the Level and Variability of High-Tech Firms Market Values.” NBER working paper 7201, Los Angeles: University of California.

DiMasi J. A. 2001. “New Drug Development in the United States from 1963 to 1999.” Clinical Pharmacology & Therapeutics 69 (5): 286–296.

Financial Accounting Standards Board. 2002. “Disclosure of Information about Intangible Assets Not Recognized in Financial Statements.” Norwalk, CT: FASB.

Fisher W. O. 2002. “Key Disclosure Issues for Life Sciences Companies: FDA Product Approval, Clinical Test Results, and Government Inspections.” Michigan Telecommunications and Technology Law Review 8 (115): 115–193.

Grabowski H. Vernon J. , 1994. “Returns to R&D on New Drug Introductions in the 1980s.” Journal of Health Economics 13 (4): 383–407.

Halperin M. Chakrabarti A. . 1987. “Firm and Industry Characteristics Influencing Publications of Scientists in Large American Companies.” R&D Management 17 (3): 167–73.

Hand J. R. M. 2001. “The Market Valuation of Biotechnology Firms and Biotechnology R&D.” Working paper, University of North Carolina, Chapel Hill.

Healy P. M. Myers S. C. Howe C. D. . 2002. “R&D Accounting and the Tradeoff Between Relevance and Objectivity.” Journal of Accounting Research 40 (3): 677–710.

Henderson R. Cockburn I. . 1994. “Measuring Competence: Exploring Firm Effects in Pharmaceutical Research.” Strategic Management Journal 15:63–84.

Holthausen R. W. Watts R. L. . 2001. “The Relevance of the Value-Relevance Literature for Financial Accounting Standard Setting.” Journal of Accounting and Economics 31 (1–3): 3–75.

Joos P. 2002. “Explaining Cross-Sectional Differences in Market-to-Book Ratios in the Pharmaceutical Industry.” Working paper, University of Rochester.

Joy R. 1997. Industry Surveys: Biotechnology. New York: Standard & Poor's, Inc.

Misakian A. L. Bero L. A. . 1998. “Publication Bias and Research on Passive Smoking: Comparison of Published and Unpublished Studies.” Journal of American Medical Association 280 (3): 250–253.

Mullen A. Blunck M. Kalbfleisch M. Moeller K. E. Rohbeck H. G. . 1997. “Assessment: From an Industrial User Perspective, of Some Major Competitor Information Files on Pharmaceutical Development Products.” Journal of Information Science 23 (1): 9–23.

PhRMA. 1999. Pharmaceutical Industry Profile 1999. Washington, D.C.: Pharmaceutical Research and Manufacturers of America.

Ronen J. 2001. “On R&D Capitalization and Value Relevance: A Commentary.” Journal of Accounting and Public Policy 20:241–254.

Shortridge R. 2001. “Market Valuation of Successful versus Non-Successful R&D Efforts in the Pharmaceutical Industry.” Working Paper, Ball State University.

Torabzadeh K. M. Woodruff C. G. Sen N. . 1998. “FDA Decisions on New Drug Applications and the Market Value of Pharmaceutical Firms.” American Business Review 16 (2): 42–50.